Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-06
DOI
10.1038/s41467-018-05626-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
- (2017) A. J. van der Wekken et al. PLoS One
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- The WNT-less wonder: WNT-independentβ-catenin signaling
- (2016) Zackie Aktary et al. Pigment Cell & Melanoma Research
- Notch-Induced Expression of FZD7 Requires Noncanonical NOTCH3 Signaling in Human Breast Epithelial Cells
- (2016) Vasudeva Bhat et al. STEM CELLS AND DEVELOPMENT
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non–Small-Cell Lung Cancer
- (2015) Silvia Novello JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation
- (2015) Yosuke Togashi et al. Journal of Thoracic Oncology
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
- (2015) Philippe Depeille et al. NATURE CELL BIOLOGY
- Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
- (2015) Anil Belur Nagaraj et al. Oncotarget
- EGFR Blockade Enriches for Lung Cancer Stem-like Cells through Notch3-Dependent Signaling
- (2014) R. R. Arasada et al. CANCER RESEARCH
- -Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
- (2014) S. Nakayama et al. CANCER RESEARCH
- Safely targeting cancer stem cells via selective catenin coactivator antagonism
- (2014) Heinz-Josef Lenz et al. CANCER SCIENCE
- SAMD9L Inactivation Promotes Cell Proliferation via Facilitating G1-S Transition in Hepatitis B Virus-associated Hepatocellular Carcinoma
- (2014) Qun Wang et al. International Journal of Biological Sciences
- Regulated Proteolysis of NOTCH2 and NOTCH3 Receptors by ADAM10 and Presenilins
- (2014) A. J. Groot et al. MOLECULAR AND CELLULAR BIOLOGY
- Impact of Mesenchymal Stem Cell secreted PAI-1 on colon cancer cell migration and proliferation
- (2013) Niamh M. Hogan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Rare Population of CD24+ITGB4+Notchhi Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal
- (2013) Yanyan Zheng et al. CANCER CELL
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
- (2013) Tianhong Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary Cancer
- (2012) K. D. Proffitt et al. CANCER RESEARCH
- Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
- (2012) Matias Casás-Selves et al. CANCER RESEARCH
- HB-EGF Is Necessary and Sufficient for Müller Glia Dedifferentiation and Retina Regeneration
- (2012) Jin Wan et al. DEVELOPMENTAL CELL
- Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
- (2012) A. Gurney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Non-canonical Notch signaling: emerging role and mechanism
- (2012) Peter Andersen et al. TRENDS IN CELL BIOLOGY
- Histone H1 Recruitment by CHD8 Is Essential for Suppression of the Wnt- -Catenin Signaling Pathway
- (2011) M. Nishiyama et al. MOLECULAR AND CELLULAR BIOLOGY
- Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
- (2011) Yongsheng Wang et al. Therapeutic Advances in Medical Oncology
- Wnt/β-catenin Signaling in Normal and Cancer Stem Cells
- (2011) Kenneth C. Valkenburg et al. Cancers
- Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling
- (2010) J. P. Sullivan et al. CANCER RESEARCH
- Plasminogen Activator Inhibitor-1 Is a Transcriptional Target of the Canonical Pathway of Wnt/β-Catenin Signaling
- (2010) Weichun He et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways
- (2010) Naoko Takebe et al. Nature Reviews Clinical Oncology
- The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
- (2009) Raphael Kopan et al. CELL
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
- (2009) Shih-Min A. Huang et al. NATURE
- A regulatory pathway involving Notch1/β-catenin/Isl1 determines cardiac progenitor cell fate.
- (2009) Chulan Kwon et al. NATURE CELL BIOLOGY
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now